|
EP1648511A1
(en)
*
|
2003-07-29 |
2006-04-26 |
Morphotek, Inc. |
Antibodies and methods for generating genetically altered antibodies with enhanced effector function
|
|
EP1716179A2
(en)
*
|
2004-02-12 |
2006-11-02 |
Morphotek, Inc. |
Monoclonal antibodies that specifically bind to folate receptor alpha
|
|
EP2322560B1
(en)
*
|
2005-03-10 |
2013-09-04 |
Morphotek, Inc. |
Anti-mesothelin antibodies
|
|
JP2009521206A
(ja)
*
|
2005-04-22 |
2009-06-04 |
モルフォテック、インク． |
免疫エフェクター活性を有する葉酸受容体アルファ陽性細胞に内部移行する抗体
|
|
KR100694508B1
(ko)
*
|
2005-05-24 |
2007-03-13 |
울산대학교 산학협력단 |
Ｈｂｂｋ４항체를 포함하는 암 질환 치료용 약학조성물및 이를 이용한 암의 면역치료 방법
|
|
US7943133B2
(en)
*
|
2006-02-02 |
2011-05-17 |
Boston Biocom Llc |
Mesothelin antibody protein fusions and methods of use
|
|
US7795411B2
(en)
|
2006-10-05 |
2010-09-14 |
Fred Hutchinson Cancer Research Center |
Vectors for expressing in vivo biotinylated recombinant proteins
|
|
CN111518218A
(zh)
*
|
2006-11-02 |
2020-08-11 |
阿塞勒隆制药公司 |
Alk1受体和配体拮抗剂及其用途
|
|
SI2195017T1
(sl)
*
|
2007-10-01 |
2015-01-30 |
Bristol-Myers Squibb Company |
Človeška protitelesa, ki vežejo mezotelin in njihova uporaba
|
|
HUE027358T2
(en)
*
|
2007-11-26 |
2016-09-28 |
Bayer Ip Gmbh |
Anti-mesothelin antibodies and their applications
|
|
AU2009228361A1
(en)
*
|
2008-03-27 |
2009-10-01 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Human anti-mesothelin monoclonal antibodies
|
|
JP2010014691A
(ja)
*
|
2008-06-20 |
2010-01-21 |
Igaku Seibutsugaku Kenkyusho:Kk |
腹水中のメソテリン及び／又は巨核球増強因子を検出するための方法、キット、試薬及び装置
|
|
AU2010230063B2
(en)
*
|
2009-03-24 |
2015-06-25 |
The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
Anti-mesothelin antibodies
|
|
UY32560A
(es)
*
|
2009-04-29 |
2010-11-30 |
Bayer Schering Pharma Ag |
Inmunoconjugados de antimesotelina y usos de los mismos
|
|
LT2552961T
(lt)
|
2010-03-30 |
2018-02-12 |
Janssen Biotech, Inc. |
Humanizuoti il-25 antikūnai
|
|
PE20170917A1
(es)
*
|
2010-12-20 |
2017-07-12 |
Genentech Inc |
Anticuerpos anti-mesotelina e inmunoconjugados
|
|
US10233240B1
(en)
*
|
2011-04-18 |
2019-03-19 |
The Regents Of The University Of California |
Methods for treating cholestatic liver fibrosis
|
|
MX2013012905A
(es)
|
2011-05-06 |
2014-04-25 |
Us Gov Health & Human Serv |
Inmunotoxina recombinante dirigida a la mesotelina.
|
|
US9493566B2
(en)
*
|
2012-02-17 |
2016-11-15 |
Seattle Genetics, Inc. |
Antibodies to integrin AVB6 and use of same to treat cancer
|
|
DK2828284T3
(da)
|
2012-03-20 |
2019-06-11 |
Biogen Ma Inc |
Jcv-neutraliserende antistoffer
|
|
DK2828292T3
(da)
|
2012-03-20 |
2019-01-02 |
Biogen Ma Inc |
Jcv-neutraliserende antistoffer
|
|
CA2868121C
(en)
|
2012-03-23 |
2021-06-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-mesothelin chimeric antigen receptors
|
|
WO2014004549A2
(en)
|
2012-06-27 |
2014-01-03 |
Amgen Inc. |
Anti-mesothelin binding proteins
|
|
WO2014031476A1
(en)
*
|
2012-08-21 |
2014-02-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Mesothelin domain-specific monoclonal antibodies and use thereof
|
|
EP3221356B1
(en)
|
2014-11-20 |
2020-09-02 |
F.Hoffmann-La Roche Ag |
T cell activating bispecific antigen binding molecules against folr1 and cd3
|
|
BR112017010513A2
(pt)
|
2014-11-20 |
2018-04-03 |
F. Hoffmann-La Roche Ag |
?cadeias leves comuns e métodos de uso?
|
|
US11161907B2
(en)
|
2015-02-02 |
2021-11-02 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
BR112017024757A2
(pt)
|
2015-05-18 |
2018-11-13 |
TCR2 Therapeutics Inc. |
composições e métodos para reprogramação de tcr utilizando proteínas de fusão
|
|
KR20180055824A
(ko)
*
|
2015-08-21 |
2018-05-25 |
카르스젠 테라퓨틱스 리미티드 |
항 메소텔린 완전 인간 항체 및 메소텔린을 타겟팅하는 면역효과 세포
|
|
KR101782487B1
(ko)
*
|
2015-09-24 |
2017-09-27 |
재단법인 목암생명과학연구소 |
신규 항-메소텔린 항체 및 이를 포함하는 조성물
|
|
HK1254967A1
(zh)
*
|
2015-10-02 |
2019-08-02 |
豪夫迈‧罗氏有限公司 |
结合间皮素和cd3的双特异性t细胞活化性抗原结合分子
|
|
EP3359168A4
(en)
|
2015-10-06 |
2019-08-07 |
Regents of the University of Minnesota |
THERAPEUTIC COMPOUNDS AND METHOD
|
|
BR112018013074A2
(en)
|
2015-12-30 |
2018-12-11 |
Novartis Ag |
immune effector cell therapies with enhanced efficacy
|
|
CA3016287A1
(en)
|
2016-03-04 |
2017-09-08 |
Novartis Ag |
Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
|
|
MA43724B1
(fr)
*
|
2016-03-22 |
2023-06-28 |
Hoffmann La Roche |
Molécules bispécifiques de cellules t activées par une protéase
|
|
LT3433280T
(lt)
|
2016-03-22 |
2023-07-10 |
F. Hoffmann-La Roche Ag |
Proteazės aktyvuojamos t ląstelei bispecifinės molekulės
|
|
US11549099B2
(en)
|
2016-03-23 |
2023-01-10 |
Novartis Ag |
Cell secreted minibodies and uses thereof
|
|
EP3443096B1
(en)
|
2016-04-15 |
2023-03-01 |
Novartis AG |
Compositions and methods for selective expression of chimeric antigen receptors
|
|
EP3448421B1
(en)
*
|
2016-04-29 |
2021-11-03 |
The Board of Trustees of the Leland Stanford Junior University |
Methods and compositions for the prevention and treatment of surgical adhesions
|
|
KR20190014525A
(ko)
*
|
2016-05-27 |
2019-02-12 |
애브비 바이오테라퓨틱스 인크. |
면역 조절 단백질과 종양 항원을 결합하는 이중특이적 결합 단백질
|
|
BR112018076525A2
(pt)
|
2016-06-20 |
2019-04-02 |
F-Star Beta Limited |
membros de ligação a lag-3
|
|
GB201612520D0
(en)
|
2016-07-19 |
2016-08-31 |
F-Star Beta Ltd |
Binding molecules
|
|
EP3490590A2
(en)
|
2016-08-01 |
2019-06-05 |
Novartis AG |
Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
|
|
WO2018026953A1
(en)
|
2016-08-02 |
2018-02-08 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
MX2019003899A
(es)
|
2016-10-07 |
2019-08-14 |
Tcr2 Therapeutics Inc |
Composiciones y metodos para reprogramacion de receptores de linfocitos t mediante el uso de proteinas de fusion.
|
|
AU2017363311A1
(en)
|
2016-11-22 |
2019-06-13 |
TCR2 Therapeutics Inc. |
Compositions and methods for TCR reprogramming using fusion proteins
|
|
IL324632A
(en)
|
2016-12-01 |
2026-01-01 |
Regeneron Pharma |
Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging
|
|
EP3574005B1
(en)
|
2017-01-26 |
2021-12-15 |
Novartis AG |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
|
EP3638295A1
(en)
|
2017-06-13 |
2020-04-22 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
JP7489316B2
(ja)
|
2017-12-19 |
2024-05-23 |
エフ－スター セラピューティクス リミテッド |
Ｐｄ－ｌｉ抗原結合部位を有するｆｃ結合断片
|
|
EP3784351A1
(en)
|
2018-04-27 |
2021-03-03 |
Novartis AG |
Car t cell therapies with enhanced efficacy
|
|
EP3788369A1
(en)
|
2018-05-01 |
2021-03-10 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
|
WO2019227003A1
(en)
|
2018-05-25 |
2019-11-28 |
Novartis Ag |
Combination therapy with chimeric antigen receptor (car) therapies
|
|
US20210123075A1
(en)
|
2018-06-08 |
2021-04-29 |
Novartis Ag |
Compositions and methods for immunooncology
|
|
EP3807321A4
(en)
*
|
2018-06-18 |
2022-03-02 |
Anwita Biosciences, Inc. |
ANTI-MESOTHELIN CONSTRUCTS AND USES THEREOF
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
GB201811408D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
CD137 Binding Molecules
|
|
GB201811404D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Anti-CD137 Antibodies
|
|
AU2019301206B2
(en)
|
2018-07-12 |
2025-10-30 |
Invox Pharma Limited |
Antibody molecules that bind CD137 and OX40
|
|
GB201811403D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Antibody molecules
|
|
GB201811415D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Anti-Mesothelin Anti bodies
|
|
GB201811450D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Delta Ltd |
Mesothelin and CD137 binding molecules
|
|
GB201811410D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
OX40 Binding molecules
|
|
PL3820569T3
(pl)
|
2018-07-12 |
2025-07-14 |
Invox Pharma Limited |
Cząsteczki przeciwciał, które wiążą PD-L1 oraz CD137
|
|
MX2021002225A
(es)
|
2018-08-30 |
2021-07-16 |
Tcr2 Therapeutics Inc |
Composiciones y metodos para la reprogramacion de tcr mediante el uso de proteinas de fusion.
|
|
US12331320B2
(en)
|
2018-10-10 |
2025-06-17 |
The Research Foundation For The State University Of New York |
Genome edited cancer cell vaccines
|
|
AU2019361096A1
(en)
|
2018-10-19 |
2021-06-03 |
Regents Of The University Of Minnesota |
NK engager molecules and methods of use thereof
|
|
WO2020092631A1
(en)
*
|
2018-10-31 |
2020-05-07 |
Fred Hutchinson Cancer Research Center |
Compositions and methods for detecting and treating cancers characterized by expression of mesothelin
|
|
WO2020128972A1
(en)
|
2018-12-20 |
2020-06-25 |
Novartis Ag |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
CN109705219B
(zh)
*
|
2019-01-08 |
2020-11-13 |
上海霖科生物科技有限公司 |
与间皮素结合的单克隆抗体及其制备方法
|
|
BR112021015672A2
(pt)
|
2019-02-15 |
2021-10-05 |
Novartis Ag |
Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona substituída e usos dos mesmos
|
|
ES3032659T3
(en)
|
2019-02-15 |
2025-07-23 |
Novartis Ag |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
KR20220035908A
(ko)
*
|
2019-06-19 |
2022-03-22 |
실버백 테라퓨틱스, 인크. |
항-메소텔린 항체 및 이의 면역접합체
|
|
IL293195A
(en)
|
2019-12-05 |
2022-07-01 |
Seagen Inc |
Anti-avb6 antibodies and antibody-drug conjugates
|
|
KR20220116257A
(ko)
|
2019-12-20 |
2022-08-22 |
노파르티스 아게 |
골수섬유증 및 골수이형성 증후군을 치료하기 위한, 데시타빈 또는 항 pd-1 항체 스파르탈리주맙을 포함하거나 또는 포함하지 않는, 항 tim-3 항체 mbg453 및 항 tgf-베타 항체 nis793의 조합물
|
|
JP2023507323A
(ja)
|
2019-12-20 |
2023-02-22 |
アムジエン・インコーポレーテツド |
固形腫瘍の治療のためのメソセリン標的化ｃｄ４０アゴニスト多重特異性抗体コンストラクト
|
|
CN116096862A
(zh)
|
2020-06-11 |
2023-05-09 |
诺华股份有限公司 |
Zbtb32抑制剂及其用途
|
|
CN115916199A
(zh)
|
2020-06-23 |
2023-04-04 |
诺华股份有限公司 |
包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案
|
|
US20230271940A1
(en)
|
2020-08-03 |
2023-08-31 |
Novartis Ag |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
TW202321296A
(zh)
|
2021-10-06 |
2023-06-01 |
美商鏈接免疫療法公司 |
抗間皮素抗原結合分子及其用途
|
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
|
WO2024102954A1
(en)
|
2022-11-10 |
2024-05-16 |
Massachusetts Institute Of Technology |
Activation induced clipping system (aics)
|
|
EP4701654A2
(en)
|
2023-04-25 |
2026-03-04 |
Arsenal Biosciences, Inc. |
Novel receptors for transcription regulation
|
|
EP4720059A1
(en)
|
2023-05-24 |
2026-04-08 |
Kumquat Biosciences Inc. |
Heterocyclic compounds and uses thereof
|
|
WO2025235862A1
(en)
|
2024-05-10 |
2025-11-13 |
Inndura Therapeutics Inc. |
A modified immune cell receptor comprising a target-binding domain and the extracellular domain of cd16a
|